Drugs / PLASMA PROTEIN FRACTION
PLASMA PROTEIN FRACTION
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase not applicable1 trial | ||||||
| — | NCT05033704 | Sep 2019 → Sep 2021 | disorder of mineral absorption and transport, disseminated intravascular coagulation | Hamad Medical Corporation | Unknown | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT02997969 Comparator | Jun 2016 → Jul 2018 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
Evidence & citations 10 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PLASMA PROTEIN FRACTION | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108773 ↗ |
| Known as | Human plasma protein | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108773 ↗ |
| Known as | human plasma protein fraction | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05033704 ↗ |
| Known as | Human plasma proteins | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108773 ↗ |
| Known as | Plasma protein | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108773 ↗ |
| Known as | Plasma protein fraction (human) | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108773 ↗ |
| Known as | PPF | “Infusion of 5% human plasma protein fraction PPF.” NCT05033704 ↗ |
| Known as | Protein/MF59 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02997969 ↗ |
| Modality | Vaccine | “Protein/MF59 vaccine” NCT02997969 ↗ |
| Route | Intramuscular | “administered as 0.5 mL IM” NCT02997969 ↗ |